39 results on '"Duffy, Carol I"'
Search Results
2. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction
3. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial
4. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients
5. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure
6. Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry
7. Angiotensin-Neprilysin Inhibition in Black Americans
8. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial
9. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists
10. Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction
11. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF
12. IMPACT OF HEART FAILURE HOSPITALIZATION ON GUIDELINE-DIRECTED MEDICAL THERAPY PRESCRIBING PATTERNS AMONG PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: AN ANALYSIS FROM CHAMP-HF
13. Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus
14. Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF)
15. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction
16. Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial
17. Association of Changes in Heart Failure Treatment With Patients’ Health Status
18. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
19. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
20. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction
21. Target Doses of Heart Failure Medical Therapy and Blood Pressure
22. EFFECT OF SACUBITRIL/VALSARTAN ON BIOMARKERS OF MYOCARDIAL STRESS IN PATIENTS HOSPITALIZED WITH ACUTE HEART FAILURE IN PIONEER-HF
23. EFFECT OF SACUBITRIL/VALSARTAN INITIATION ON 30-DAY READMISSIONS AFTER A HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE: A SECONDARY ANALYSIS OF THE PIONEER-HF TRIAL
24. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
25. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States
26. Use of Target Doses of Guideline Directed Medical Therapy in Heart Failure by Systolic Blood Pressure: Insights from the CHAMP-HF Registry
27. Association between Sacubitril/Valsartan Initiation and Health Status Outcomes inHeart Failure with Reduced Ejection Fraction:Findings from the CHAMP-HF Registry
28. Medical Therapy for Heart Failure With Reduced Ejection Fraction
29. Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial
30. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial
31. Health Status Variation Across Practices in Outpatients With Heart Failure
32. Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry
33. Abstract 255: The Development of an Observational Registry of Treatment Patterns in US Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
34. Iron sucrose or ferric gluconate?
35. Color Doppler and two-dimensional echocardiographic determination of the mechanism of aortic regurgitation with surgical correlation
36. Progression of aortic stenosis in 394 patients: Relation to changes in myocardial and mitral valve dysfunction
37. Transesophageal Echocardiographic Assessment of Aortic Coarctation Using Color, Flow-Directed Doppler Sampling
38. Importance of Sampling Both Pulmonary Veins in Grading Mitral Regurgitation by Transesophageal Echocardiography
39. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.